¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chronic hypocomplementemic glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • chronic
    ¸¸¼º-
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic atrophic gastritis
    ¸¸¼ºÀ§ÃàÀ§¿°
  • chronic bronchitis
    ¸¸¼º±â°üÁö¿°
  • chronic exposure
    ¸¸¼º³ëÃâ
  • chronic fatigue syndrome
    ¸¸¼ºÇÇ·ÎÁõÈıº
  • chronic granulomatous disease
    ¸¸¼ºÀ°¾ÆÁ¾º´
  • chronic hepatitis
    ¸¸¼º°£¿°
  • chronic hypertrophic rhinitis
    ¸¸¼ººñÈÄÄÚ¿°, ¸¸¼ººñÈĺñ¿°
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diffuse proliferative glomerulonephritis
    »êÀçÁõ½ÄÅ丮ÄáÆÏ¿°, ¹Ì¸¸Áõ½Ä»ç±¸Ã¼½Å¿°
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • exudative proliferative glomerulonephritis
    »ïÃâÁõ½ÄÅ丮ÄáÆÏ¿°, »ïÃâÁõ½Ä»ç±¸Ã¼½Å¿°
  • focal glomerulonephritis
    ÃÊÁ¡Å丮ÄáÆÏ¿°, ÃÊÁ¡»ç±¸Ã¼½Å¿°
  • focal embolic glomerulonephritis
    ÃÊÁ¡»öÀüÅ丮ÄáÆÏ¿°, ÃÊÁ¡»öÀü»ç±¸Ã¼½Å¿°
  • focal proliferative glomerulonephritis
    ÃÊÁ¡Áõ½ÄÅ丮ÄáÆÏ¿°, ÃÊÁ¡Áõ½Ä»ç±¸Ã¼½Å¿°
  • focal segmental glomerulonephritis
    ÃÊÁ¡ºÐÀýÅ丮ÄáÆÏ¿°, ÃÊÁ¡ºÐÀý»ç±¸Ã¼½Å¿°
  • glomerulonephritis
    Å丮ÄáÆÏ¿°, »ç±¸Ã¼½Å¿°
  • intercapillary glomerulonephritis
    ¸ð¼¼°üÅ丮ÄáÆÏ¿°, ¸ð¼¼°ü°£»ç±¸Ã¼½Å¿°
  • membranoproliferative glomerulonephritis
    ¸·Áõ½ÄÅ丮ÄáÆÏ¿°, ¸·Áõ½Ä»ç±¸Ã¼½Å¿°
  • membranous glomerulonephritis
    ¸·Å丮ÄáÆÏ¿°, ¸·»ç±¸Ã¼½Å¿°
  • mesangiocapillary glomerulonephritis
    »çÀÌÁú¸ð¼¼°üÅ丮ÄáÆÏ¿°, »ç±¸Ã¼°£Áú¸ð¼¼°ü»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glomerulonephritis,focal embolic
    ÃÊÁ¡¼º »öÀü¼º
  • glomerulonephritis,focal proliferative
    ÃÊÁ¡¼º Áõ½Ä¼º
  • glomerulonephritis,membranoproliferative
    ¸·Áõ½Ä¼º
  • glomerulonephritis,membranous
    ¸·¼º
  • poststreptococcal(proliferative) glomerulonephritis
    ¿¬¼â»ó±¸±Õ°¨¿°ÈÄ(Áõ½Ä¼º) »ç±¸Ã¼½Å¿°(ææáðßÒϹжÊïæøý­(ñòãÖàõ) ÞêϹô÷ãìæú)
  • proliferative glomerulonephritis
    Áõ½Ä¼º »ç±¸Ã¼½Å¿°(ñòãÖàõ ÞêϹô÷ãìæú)
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intercapillary glomerulonephritis
    ¸ð¼¼(Ç÷)°ü°£»ç±¸Ã¼½Å¿°.
  • membranous glomerulonephritis
    ¸·¼º»ç±¸ ü½Å¿°(¡­ÞêϹô÷ãìæú).
  • membranous glomerulonephritis
    ¸·¼º»ç±¸Ã¼½Å¿°(¡­Þêϳô÷ãìæú)
  • mesangiocapillary glomerulonephritis
    »ç±¸Ã¼°£Áú (¸Þ»êÁöÀ½)¸ð¼¼°ü¼º(Ù¾á¬Î·àõ) »ç±¸Ã¼½Å¿°
  • poststreptococcal(proliferative) glomerulonephritis
    ¿¬¼â»ó±¸±Õ°¨¿°ÈÄ(Áõ½Ä¼º) »ç±¸Ã¼½Å¿°(ææáðßÒϹжÊïæøý­(ñòãÖàõ) ÞêϹô÷ãìæú)
  • proliferative glomerulonephritis
    Áõ½Ä¼º »ç±¸Ã¼½Å¿°(ñòãÖàõ ÞêϹô÷ãìæú)
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú).
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú)
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú)
  • alcoholism, chronic
    ¾ËÄÚ¿Ã Áßµ¶, ¸¸¼º(¡­ñéÔ¸)
  • brain syndrome, acute, chronic
    ±Þ¼º, ¸¸¼º ³úÁõÈıº.
  • bronchitis, chronic
    ±â°üÁö¿°(¡­æú), ¸¸¼º(Ø·àõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CG cardiography; cardiogreen; choking gas; choriogenic gynecomastia; chorionic gonadotropin; chromogran...
CGN chronic glomerulonephritis
CMGN chronic membranous glomerulonephritis
CMPGN chronic membranoproliferative glomerulonephritis
CPGN chronic proliferative glomerulonephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CGN Crescentic glomerulonephritis
CrGN Crescentic glomerulonephritis
DPGN Diffuse proliferative glomerulonephritis
EAG Experimental autoimmune glomerulonephritis
iMGN Idiopathic membranous glomerulonephritis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • chronic carrier
    ¸¸¼º º¸±ÕÀÚ
  • chronic closed angle glaucoma
    ¸¸¼º Æó¼â°¢ ³ì³»Àå
  • chronic conjunctivitis
    ¸¸¼º °á¸·¿°
  • chronic cystic mastitis
    ¸¸¼º ³¶¼º À¯¹æ¿°
  • chronic dacryocystitis
    ¸¸¼º ´«¹° ÁÖ¸Ó´Ï ¿°Áõ, ¸¸¼º ´©³¶¿°
  • chronic dermatitis
    ¸¸¼º ÇǺο°
  • chronic diffuse sclerosing osteomyelitis
    ¸¸¼º ¹Ì¸¸¼º °æÈ­¼º °ñ¼ö¿°
    ¹Ì¸¸¼ºÀÇ Ä¡ÃßÁúȯ¿¡ ÀÇÇÑ °¨¿°¿¡¼­ ºñ·ÔµÈ´Ù. ³·Àº Á¤µµÀÇ °¨¿°¿¡ ´ëÇÑ °ñÀÇ Áõ½Ä¼º ¹ÝÀÀÀÌ´Ù. ³ë³âÃþÀÇ ¹«Ä¡¾Ç ºÎÀ§¿¡ ÁÖ·Î »ý±ä´Ù. Ưº°ÇÑ ¼Ò°ßÀº ¾ø´Ù. °ñÀÇ ¹Ì¸¸¼º °æÈ­°¡ ½ÉÇÏ°í ¾çÃø¼ºÀÌ´Ù. °æ°è´Â ºÒ¸í·áÇÏ´Ù. Á¶Á÷º´¸®ÇÐÀû ¼Ò°ßÀº Á¶¹ÐÇÏ°í ºÒ±ÔÄ¢ÇÑ °ñ¼ö, ¼¶À¯¼º °ñ¼ö°­ÀÌ´Ù.
  • chronic disease
    ¸¸¼º Áúȯ
    º´ÀÇ °æ°úÀÇ Àå´Ü¿¡ ÀÇÇÑ ºÐ·ù. º¸Åë 6°³¿ù ȤÀº l³â ÀÌ»ó °è¼ÓµÇ´Â ÁúȯÀ» ¸»Çϸç, ±Þ¼º Áúȯ°ú ´ëÀÀÇÑ´Ù. ±× Áõ¼¼°¡ ¿Ï¸¸ÇÏ°Ô ³ªÅ¸³ª Àå±â°£ Áö¼ÓÇϹǷΠ¸¸¼º Áõ»óÀ̶ó Çϸç, À̰͵µ ±Þ¼º Áúȯ¿¡¼­ÀÇ ±Þ¼º Áõ»ó¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀÎ ¸¸¼º ÁúÇÑÀ¸·Î´Â °áÇÙ, ³ªº´, ¸Åµ¶ µîÀÌ ÀÖ°í, ±Þ¼º Áúȯ¿¡¼­ ÀÌÇàÇÏ´Â °Íµµ ¸¹´Ù. ´Ü¼øÈ÷ ¾ËÄÚ¿Ã Áßµ¶À̳ª °üÀý ·ù¸ÓƼÁò µîÀÇ °æ¿ì´Â ¸¸¼ºÀ¸·Î º¸´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic empyema
    ¸¸¼º ³óÈä
  • chronic endemic dental fluorosis
    ¸¸¼º À¯Ç༺ Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ, ¸¸¼º dzÅ伺 Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ
  • chronic erythematous atrophic candidosis
    ¸¸¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • chronic exposure
    ¸¸¼º ³ëÃâ
  • chronic factitious disorder with physical symptom
    ¸¸¼º ÀΰøÀû Àå¾Ö ½ÅüÀû
  • chronic fatigue syndrome
    ¸¸¼º ÇÇ·Î ÁõÈıº
    ½±°Ô ÇǰïÇϰí ÁöÄ¡¸ç ¸öÀÌ ³ª¸¥ÇØÁö´Â µîÀÇ ÇÇ·Î Áõ¼¼°¡ 6°³¿ù ÀÌ»ó ¸¸¼ºÀûÀ¸·Î Áö¼ÓÇÏ´Â Áõ»ó. È®½ÇÇÑ ¿øÀÎÀº ¹àÇôÁ® ÀÖÁö ¾Ê°í, ¹ÙÀÌ·¯½º °¨¿°ÀÌ ±× ¿øÀÎÀÇ Çϳª·Î ÃßÁ¤µÈ´Ù. Æò¼Ò °Ç°­ÇÑ »ç¶÷¿¡°Ô¼­ °¨±â³ª ¸ö»ì ±â¿îÀÌ ÀÖ´Ù°¡ ÀÌ·± ÇǷΰ¡ ³ªÅ¸³­´Ù. ´ëü·Î Ưº°ÇÑ Ä¡·á°¡ ÇÊ¿ä¾øÀÌ ÀúÀý·Î Ä¡À¯µÇ³ª ÇǷθ¦ ´À³¢°Ô ÇÏ´Â ´Ù¸¥ Áúº´ÀÇ À¯¹«¸¦ È®ÀÎÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. ƯÈ÷ ½ºÆ®·¹½º, ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö µî°ú °°Àº Á¤½ÅÀû ¹®Á¦°¡ ¾à 50 %¸¦ Â÷ÁöÇϸç, ½ÅüÀû ÁúȯÀ¸·Î´Â ´ç´¢º´, °©»ó¼± Áúȯ, ¸¸¼º È£Èí±â Áúȯ, ºóÇ÷, °áÇÙ, °£¿°, ½ÅÀå ÁúȯÀ̳ª ¾Ï µî¿¡ ÀÇÇØ¼­µµ ¸¸¼ºÀû ÇǷΰ¨À» ´À³¥ ¼ö ÀÖ´Ù. ÀÌ¿Í °°Àº ÁúȯÀÌ ¾ø´Â °ÍÀÌ ÆÇ¸íµÇ¸é ¸¸¼º ÇÇ·Î ÁõÈıºÀ¸·Î Áø´ÜÇÒ ¼ö ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
membranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane.
The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests.
Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(26 Mar 1998)
mesangial proliferative glomerulonephritis <nephrology, pathology> Inflammation of the kidney glomerulus (blood filtering portion of the kidney) due to the abnormal deposition of IgM antibody in the mesangium layer of the glomerular capillary. A form of glomerulonephritis that appears to be caused by an abnormal immune response. This disorder generally manifests as nephrotic syndrome.
Symptoms include swelling, dark urine, weight gain, hypertension, anorexia and bloody urine.
Acronym: MPGN
(05 Jan 1998)
mesangiocapillary glomerulonephritis <nephrology, pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
crescentic glomerulonephritis <nephrology, pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
proliferative glomerulonephritis Glomerulonephritis with hypercellularity of glomeruli due to proliferation of endothelial or mesangial cells, occurring in acute glomerulonephritis and membranoproliferative glomerulonephritis.
(05 Mar 2000)
segmental glomerulonephritis Glomerulonephritis affecting only part of a glomerulus or glomeruli.
Synonym: local glomerulonephritis.
(05 Mar 2000)
necrotising glomerulonephritis <pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
subacute glomerulonephritis Undesirable term for glomerulonephritis with proteinuria, haematuria and azotemia persisting for many weeks; renal changes are variable, including those of rapidly progressive and membranoproliferative glomerulonephritis.
Synonym: subacute nephritis.
(05 Mar 2000)
diffuse glomerulonephritis Glomerulonephritis affecting most of the renal glomeruli; it may lead to azotemia.
(05 Mar 2000)
immune complex glomerulonephritis Immune complexes are deposited in the renal glomerulus where they bind complement and initiate an inflammatory process attracting neutrophils and macrophages resulting in an alteration of the basement layer of the kidney. The disease state can lead to ultimate destruction of the glomerulus and renal failure.
(05 Mar 2000)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
extramembranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane. The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests. Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(27 Sep 1997)
exudative glomerulonephritis Glomerulonephritis with infiltration of glomeruli by polymorphonuclear leukocytes, occurring in acute glomerulonephritis.
(05 Mar 2000)
focal embolic glomerulonephritis Glomerulonephritis associated with subacute bacterial endocarditis, frequently producing microscopic haematuria without azotemia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á